ONCO Overview

Financing Transaction Details: Onconetix, Inc. completed a private placement on September 22, 2025, raising approximately $12.9 million through the sale of Series D Convertible Preferred Stock and warrants, with a portion of the proceeds used to pay off debt to Veru, Inc.

Use of Proceeds: The company plans to utilize the remaining funds for costs related to terminating a previous business combination with Ocuvex, Inc., as well as for working capital and general corporate purposes.

Merger Termination: Onconetix, Inc. and Ocuvex Therapeutics, Inc. have mutually terminated their merger agreement, deciding to pursue independent paths for the benefit of their stakeholders.

Future Plans: Ocuvex has received its New Jersey state pharmaceutical license and is set to launch its product Omlonti soon, while Onconetix remains focused on its men's health and oncology solutions.

Meta Platforms Financial Results: Meta Platforms, Inc. reported second-quarter revenue of $47.52 billion and earnings of $7.14 per share, both exceeding analyst expectations, leading to an 11.7% increase in pre-market trading.

Stock Movements: Various stocks experienced significant pre-market movements, with VerifyMe, Inc. rising 57.4% after a partnership announcement, while Align Technology, Inc. fell 34.2% due to missed earnings estimates.

Investigation of Mergers: Halper Sadeh LLC is investigating potential violations of federal securities laws related to mergers involving Onconetix, Waters Corporation, and Longevity Health Holdings, focusing on shareholder rights and options.

Legal Support for Shareholders: The law firm offers free consultations to shareholders affected by these mergers, aiming to seek increased consideration and corporate reforms on a contingent fee basis.

Class Action Investigation: Monteverde & Associates PC is investigating Onconetix, Inc.'s merger with Ocuvex Therapeutics, where Ocuvex shareholders will own approximately 90% of the combined company post-merger.

Firm's Credentials: The firm, recognized as a Top 50 Class Action Firm, has successfully recovered millions for shareholders and offers free consultations for those concerned about their investments in the involved companies.